Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Lennart Tonneijck; Mark M. Smits; Marcel H.A. Muskiet; Trynke Hoekstra; Mark H.H. Kramer; A. H.Jan Danser; Piet M. Ter Wee; Michaela Diamant; Jaap A. Joles; Daniel H. van Raalte

doi:10.2337/dc19-er03

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet, Trynke Hoekstra, Mark H.H. Kramer, A. H.Jan Danser, Piet M. Ter Wee, Michaela Diamant, Jaap A. Joles, Daniel H. van Raalte

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Number of pages	1
Journal	Diabetes Care
Volume	42
Issue number	3
DOIs	https://doi.org/10.2337/dc19-er03
Publication status	Published - 1 Mar 2019

Access to Document

10.2337/dc19-er03

Cite this

Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2019). Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050. Diabetes Care, 42(3). https://doi.org/10.2337/dc19-er03

@article{c777fcd2e2254ae8b6978a6c18ae6d5a,

title = "Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050",

author = "Lennart Tonneijck and Smits, {Mark M.} and Muskiet, {Marcel H.A.} and Trynke Hoekstra and Kramer, {Mark H.H.} and Danser, {A. H.Jan} and {Ter Wee}, {Piet M.} and Michaela Diamant and Joles, {Jaap A.} and {van Raalte}, {Daniel H.}",

year = "2019",

month = mar,

day = "1",

doi = "10.2337/dc19-er03",

language = "English",

volume = "42",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "3",

}

Tonneijck, L , Smits, MM , Muskiet, MHA , Hoekstra, T, Kramer, MHH, Danser, AHJ, Ter Wee, PM, Diamant, M, Joles, JA & van Raalte, DH 2019, 'Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050', Diabetes Care, vol. 42, no. 3. https://doi.org/10.2337/dc19-er03

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes : A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050. / Tonneijck, Lennart ; Smits, Mark M.; Muskiet, Marcel H.A. et al.

In: Diabetes Care, Vol. 42, No. 3, 01.03.2019.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes

T2 - A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

AU - Tonneijck, Lennart

AU - Smits, Mark M.

AU - Muskiet, Marcel H.A.

AU - Hoekstra, Trynke

AU - Kramer, Mark H.H.

AU - Danser, A. H.Jan

AU - Ter Wee, Piet M.

AU - Diamant, Michaela

AU - Joles, Jaap A.

AU - van Raalte, Daniel H.

PY - 2019/3/1

Y1 - 2019/3/1

UR - http://www.scopus.com/inward/record.url?scp=85061964671&partnerID=8YFLogxK

U2 - 10.2337/dc19-er03

DO - 10.2337/dc19-er03

M3 - Comment/Letter to the editor

C2 - 30674545

AN - SCOPUS:85061964671

VL - 42

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 3

ER -

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Access to Document

Other files and links

Cite this